Zacks Investment Research on MSN
Bolt Biotherapeutics, Inc. (BOLT) reports Q4 loss, tops revenue estimates
Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $3.84 per share versus the Zacks Consensus Estimate of a loss of $4.3. This compares to a loss of $7.6 per share a year ago. These ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results